Cargando…

Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer

Skin deposits from breast cancer can present serious therapeutic problems, especially when resistant to conventional therapy. Topical application of a cytotoxic drug may represent an attractive new treatment modality devoid of major systemic toxicity. Miltefosine was selected because of its efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Terwogt, J M M, Mandjes, I A M, Sindermann, H, Beijnen, J H, ten Bokkel Huinink, W W
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1999
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362219/ https://www.ncbi.nlm.nih.gov/pubmed/10098751 http://dx.doi.org/10.1038/sj.bjc.6690184

Ejemplares similares

Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients
por: Malingré, M M, et al.
Publicado: (2001)

Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.
por: Herben, V. M., et al.
Publicado: (1997)

Oral topotecan: bioavailability and effect of food co-administration
por: Herben, V M M, et al.
Publicado: (1999)

The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients
por: Malingré, M M, et al.
Publicado: (2001)

MDR1 causes resistance to the antitumour drug miltefosine
por: Rybczynska, M, et al.
Publicado: (2001)

Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer
por: Helgason, H H, et al.
Publicado: (2006)

Dynamics of Parasite Clearance in Cutaneous Leishmaniasis Patients Treated with Miltefosine
por: Dorlo, Thomas P. C., et al.
Publicado: (2011)

Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation
por: Palić, Semra, et al.
Publicado: (2019)

Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks
por: Kerbusch, T, et al.
Publicado: (2004)

Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumours.
por: Dercksen, M. W., et al.
Publicado: (1993)

A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin
por: Schoemaker, N E, et al.
Publicado: (2002)

Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection
por: Kip, A. E., et al.
Publicado: (2016)

Impaired development of a miltefosine-resistant Leishmania infantum strain in the sand fly vectors Phlebotomus perniciosus and Lutzomyia longipalpis
por: Van Bockstal, Lieselotte, et al.
Publicado: (2019)

No evidence for cardiotoxicity of miltefosine()
por: Dorlo, Thomas P.C.
Publicado: (2022)

Optimum porphyrin accumulation in epithelial skin tumours and psoriatic lesions after topical application of δ-aminolaevulinic acid
por: Fritsch, C, et al.
Publicado: (1999)

Topically applied ceramide accumulates in skin glyphs
por: Zhang, Qihong, et al.
Publicado: (2015)

Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa
por: Palić, Semra, et al.
Publicado: (2020)

A phase II study of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma
por: Arends, J J, et al.
Publicado: (2005)

Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group.
por: de Wit, R., et al.
Publicado: (1995)

Evaluation of the Ability of Miltefosine Associated with Topical GM-CSF in Modulating the Immune Response of Patients with Cutaneous Leishmaniasis
por: Peixoto, Fábio, et al.
Publicado: (2020)

Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups.
por: McLeod, H. L., et al.
Publicado: (1996)

Topical Sustained Delivery of Miltefosine Via Drug-Eluting Contact Lenses to Treat Acanthamoeba Keratitis
por: Chen, Lin, et al.
Publicado: (2022)

Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer.
por: de Wit, R., et al.
Publicado: (1998)

No evidence for cardiotoxicity of miltefosine – Reply()
por: Barroso, Daniel Holanda, et al.
Publicado: (2022)

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients
por: Tellingen, O van, et al.
Publicado: (1999)

Increased Leishmania infantum resistance to miltefosine and amphotericin B after treatment of a dog with miltefosine and allopurinol
por: Gonçalves, Gustavo, et al.
Publicado: (2021)

Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group.
por: Hanauske, A. R., et al.
Publicado: (1996)

Nanocarriers Provide Sustained Antifungal Activity for Amphotericin B and Miltefosine in the Topical Treatment of Murine Vaginal Candidiasis
por: de Bastiani, Fernanda Walt Mendes da Silva, et al.
Publicado: (2020)

Pharmacokinetics of ethylenediaminemalonatoplatinum(II) (JM-40) during phase I trial.
por: Elferink, F., et al.
Publicado: (1987)

Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study.
por: Sternberg, C. N., et al.
Publicado: (1994)

Oral miltefosine for refractory Acanthamoeba keratitis
por: Hirabayashi, Kristin E., et al.
Publicado: (2019)

Repurposing of Miltefosine as an Adjuvant for Influenza Vaccine
por: Lu, Lu, et al.
Publicado: (2020)

Miltefosine enhances infectivity of a miltefosine-resistant Leishmania infantum strain by attenuating its innate immune recognition
por: Bulté, Dimitri, et al.
Publicado: (2021)

Photostability of Topical Agents Applied to the Skin: A Review
por: Kryczyk-Poprawa, Agata, et al.
Publicado: (2019)

Selective targeting of skin pathobionts and inflammation with topically applied lactobacilli
por: Lebeer, Sarah, et al.
Publicado: (2022)

Mitochondrial Proteomics of Antimony and Miltefosine Resistant Leishmania infantum
por: Vincent, Isabel M., et al.
Publicado: (2015)

Complex cutaneous infection by Leishmania mexicana treated with miltefosine
por: Sadowsky, Rachel L., et al.
Publicado: (2022)

Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance.
por: de Wit, R., et al.
Publicado: (1998)

Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study
por: Dorlo, Thomas P C, et al.
Publicado: (2017)

A Double-blind, Randomized Trial to Evaluate Miltefosine and Topical Granulocyte Macrophage Colony-stimulating Factor in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis in Brazil
por: Machado, Paulo R L, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nl5eibb4bte8pvjnveuqj0gvbc